Editas Medicine Stock Buy Hold or Sell Recommendation
| EDIT Stock | USD 3.07 0.23 6.97% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Editas Medicine is 'Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Editas Medicine given historical horizon and risk tolerance towards Editas Medicine. When Macroaxis issues a 'buy' or 'sell' recommendation for Editas Medicine, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Editas Medicine Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide. Note, we conduct extensive research on individual companies such as Editas and provide practical buy, sell, or hold advice based on investors' constraints. Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Editas |
Execute Editas Medicine Buy or Sell Advice
The Editas recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Editas Medicine. Macroaxis does not own or have any residual interests in Editas Medicine or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Editas Medicine's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Editas Medicine Trading Alerts and Improvement Suggestions
| Editas Medicine generated a negative expected return over the last 90 days | |
| Editas Medicine has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 78.12 M. Net Loss for the year was (153.22 M) with loss before overhead, payroll, taxes, and interest of (155.25 M). | |
| Editas Medicine currently holds about 452.56 M in cash with (132.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 67.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Editas Medicines SWOT analysis gene editing stock faces pivotal phase |
Editas Medicine Returns Distribution Density
The distribution of Editas Medicine's historical returns is an attempt to chart the uncertainty of Editas Medicine's future price movements. The chart of the probability distribution of Editas Medicine daily returns describes the distribution of returns around its average expected value. We use Editas Medicine price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Editas Medicine returns is essential to provide solid investment advice for Editas Medicine.
| Mean Return | -0.28 | Value At Risk | -6.68 | Potential Upside | 7.41 | Standard Deviation | 4.23 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Editas Medicine historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Editas Stock Institutional Investors
The Editas Medicine's institutional investors refer to entities that pool money to purchase Editas Medicine's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Ubs Asset Mgmt Americas Inc | 2024-06-30 | 901.6 K | Two Sigma Advisers, Llc | 2024-06-30 | 856.5 K | Avidity Partners Management Lp | 2024-06-30 | 816 K | Jpmorgan Chase & Co | 2024-06-30 | 799.2 K | Northern Trust Corp | 2024-06-30 | 737.3 K | Charles Schwab Investment Management Inc | 2024-06-30 | 733.4 K | Squarepoint Ops Llc | 2024-06-30 | 694.2 K | Integral Health Asset Management, Llc | 2024-06-30 | 675 K | Raymond James & Associates | 2024-09-30 | 561.4 K | Vanguard Group Inc | 2024-06-30 | 8 M | Blackrock Inc | 2024-06-30 | 7.8 M |
Editas Medicine Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 103.4M | (96.2M) | 63.8M | (62.0M) | (17.9M) | (17.0M) | |
| Free Cash Flow | (46.8M) | (187.0M) | (171.8M) | (181.5M) | (136.9M) | (130.1M) | |
| Depreciation | 2.8M | 4.0M | 5.1M | 6.3M | 6.1M | 3.2M | |
| Other Non Cash Items | (2.9M) | 27.6M | 1.7M | (724K) | (9.8M) | (9.3M) | |
| Capital Expenditures | 6.2M | 7.2M | 8.0M | 4.1M | 4.7M | 4.3M | |
| Net Income | (133.7M) | (116.0M) | (192.5M) | (220.4M) | (153.2M) | (160.9M) | |
| End Period Cash Flow | 239.8M | 143.6M | 207.4M | 145.4M | 123.7M | 149.0M | |
| Investments | 18.3M | (153.4M) | (46.5M) | 118.2M | (94.1M) | (98.8M) | |
| Change To Netincome | 24.3M | 50.8M | 45.1M | 28.6M | 32.9M | 36.0M | |
| Change To Inventory | 1.6M | 10.7M | (5.7M) | (3.3M) | (3.0M) | (2.9M) | |
| Change Receivables | (388K) | (5.6M) | 5.8M | (4.9M) | (4.4M) | (4.2M) |
Editas Medicine Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Editas Medicine or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Editas Medicine's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Editas stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.64 | |
β | Beta against Dow Jones | 2.17 | |
σ | Overall volatility | 4.16 | |
Ir | Information ratio | -0.11 |
Editas Medicine Volatility Alert
Editas Medicine exhibits very low volatility with skewness of 0.24 and kurtosis of 0.84. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Editas Medicine's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Editas Medicine's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Editas Medicine Fundamentals Vs Peers
Comparing Editas Medicine's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Editas Medicine's direct or indirect competition across all of the common fundamentals between Editas Medicine and the related equities. This way, we can detect undervalued stocks with similar characteristics as Editas Medicine or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Editas Medicine's fundamental indicators could also be used in its relative valuation, which is a method of valuing Editas Medicine by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Editas Medicine to competition |
| Fundamentals | Editas Medicine | Peer Average |
| Return On Equity | -0.79 | -0.31 |
| Return On Asset | -0.34 | -0.14 |
| Current Valuation | 45.81 M | 16.62 B |
| Shares Outstanding | 82.55 M | 571.82 M |
| Shares Owned By Insiders | 0.32 % | 10.09 % |
| Shares Owned By Institutions | 67.25 % | 39.21 % |
| Number Of Shares Shorted | 17.24 M | 4.71 M |
| Price To Earning | (7.02) X | 28.72 X |
| Price To Book | 1.55 X | 9.51 X |
| Price To Sales | 4.41 X | 11.42 X |
| Revenue | 78.12 M | 9.43 B |
| Gross Profit | (155.25 M) | 27.38 B |
| EBITDA | (163.12 M) | 3.9 B |
| Net Income | (153.22 M) | 570.98 M |
| Cash And Equivalents | 452.56 M | 2.7 B |
| Cash Per Share | 6.59 X | 5.01 X |
| Total Debt | 36.54 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 12.67 X | 2.16 X |
| Book Value Per Share | 2.13 X | 1.93 K |
| Cash Flow From Operations | (132.18 M) | 971.22 M |
| Short Ratio | 8.19 X | 4.00 X |
| Earnings Per Share | (2.54) X | 3.12 X |
| Target Price | 9.14 | |
| Number Of Employees | 265 | 18.84 K |
| Beta | 2.01 | -0.15 |
| Market Capitalization | 272.41 M | 19.03 B |
| Total Asset | 499.15 M | 29.47 B |
| Retained Earnings | (1.23 B) | 9.33 B |
| Working Capital | 277.61 M | 1.48 B |
| Current Asset | 144.99 M | 9.34 B |
| Current Liabilities | 6.92 M | 7.9 B |
| Net Asset | 499.15 M |
Note: Disposition of 1555 shares by Oneill Gilmore Neil of Editas Medicine at 3.4247 subject to Rule 16b-3 [view details]
Editas Medicine Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Editas . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 92761.35 | |||
| Daily Balance Of Power | (1.15) | |||
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 3.15 | |||
| Day Typical Price | 3.12 | |||
| Price Action Indicator | (0.20) | |||
| Period Momentum Indicator | (0.23) | |||
| Relative Strength Index | 41.88 |
About Editas Medicine Buy or Sell Advice
When is the right time to buy or sell Editas Medicine? Buying financial instruments such as Editas Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Editas Medicine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gold ETFs Thematic Idea Now
Gold ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Gold ETFs theme has 19 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.